Related Experiment Video
Updated: Jun 25, 2025
Robotic Enucleation of an Intra-Pancreatic Insulinoma in the Pancreatic Head
Published on: January 3, 2020
Systemic Therapy for Pancreatic Neuroendocrine Tumors
Viraj Lavingia1, Shruti Gohel1, Bhawna Sirohi2
1Dept. of Medical Oncology, HCG Cancer Center, Ahmedabad, India.
Abstract:
Pancreatic neuroendocrine tumors (PanNETs) account for approximately 2% of all pancreatic malignancies. Several systemic treatment options have been developed over the last four decades, ranging from cytotoxic chemotherapy and octreotide to newer targeted therapies like sunitinib, cabozantinib, and lenvatinib. Although surgery or liver-directed therapy remains cornerstone for management of metastatic PanNETs, however, they remain unfeasible in majority of cases. PanNETs behave differently than SI-NETs (small intestinal NET); the former is more aggressive and less responsive to somatostatin-based therapies. The optimal sequence of the systemic therapies for the advanced PanNETs depends mainly on the tumor burden, Ki-67 index, and the tempo of the disease. In the end, drawing from ENETS (European Neuroendocrine Tumor Society) and ESMO (European Society for Medical Oncology) guidelines, we propose a working algorithm for the management of advanced PanNETs, not amenable to surgery or liver-directed therapies.
Insights
Advanced pancreatic neuroendocrine tumors (PanNETs) require tailored systemic therapy. This study proposes a management algorithm based on tumor burden, Ki-67 index, and disease progression, referencing ENETS and ESMO guidelines.
Area of Science:
- Oncology
- Endocrinology
- Gastroenterology
Background:
- Pancreatic neuroendocrine tumors (PanNETs) are rare but aggressive malignancies.
- Systemic treatments for PanNETs have evolved over decades, including chemotherapy, somatostatin analogs, and targeted therapies.
- Metastatic PanNETs often preclude surgery or liver-directed treatments, necessitating effective systemic options.
Purpose of the Study:
- To develop a practical management algorithm for advanced PanNETs.
- To guide the sequencing of systemic therapies for unresectable or metastatic PanNETs.
- To integrate current guidelines from ENETS and ESMO into a clinical decision-making framework.
Main Methods:
- Review of existing systemic treatment options for PanNETs.
- Analysis of factors influencing treatment response, including tumor burden and Ki-67 index.
- Synthesis of ENETS and ESMO guidelines for advanced PanNET management.
Main Results:
- PanNETs exhibit distinct behavior compared to small intestinal NETs, often being more aggressive and less responsive to somatostatin therapies.
- Optimal systemic therapy sequencing is contingent upon disease characteristics like tumor burden, Ki-67 index, and disease tempo.
- A working algorithm is proposed for advanced PanNETs unsuitable for locoregional therapies.
Conclusions:
- A structured approach is crucial for managing advanced PanNETs.
- The proposed algorithm provides a framework for optimizing systemic therapy selection and sequencing.
- Adherence to established guidelines (ENETS, ESMO) is essential for effective PanNET management.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists